Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
Research output: Contribution to journal › Journal article › Research › peer-review
To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal and beta cell secretory capacity, measured as glucose and non-glucose induced insulin secretion during a hyperglycaemic clamp, in patients with type 2 diabetes.
|Journal||Diabetes, Obesity and Metabolism|
|Number of pages||11|
|Publication status||Published - 1 Apr 2010|
- Adult, Aged, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Double-Blind Method, Drug Administration Schedule, Female, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Peptide YY, Postprandial Period, Pyrazines, Triazoles